<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627886</url>
  </required_header>
  <id_info>
    <org_study_id>BA0859144-01</org_study_id>
    <nct_id>NCT01627886</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition</brief_title>
  <official_title>Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India and 'BONIVA®' 150 mg (Ibandronate Sodium) Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, balanced, two-treatment, two-period, two-sequence,
      crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose,
      Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's
      Laboratories Limited, India And 'BONIVA®' 150 mg (Ibandronate Sodium)Tablets Of Roche
      Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions (With As
      Many Postmenopausal Women As Possible).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Prior to dosing (0.0 hour) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 2.0, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0, 48.0 and 72.0 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibandronate sodium tablets 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boniva</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Boniva Tablets 150 mg of Roche Laboratories Inc, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate sodium</intervention_name>
    <description>Ibandronate sodium Tablets 150 mg</description>
    <arm_group_label>Ibandronate sodium tablets 150 mg</arm_group_label>
    <arm_group_label>Boniva</arm_group_label>
    <other_name>Boniva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects should be healthy human of 18 years or older.

          2. The subjects should be screened within 21 days prior to the administration of first
             dose of the study drug.

          3. The subjects should have a BMI between 19 and 30 weight in kg/ height2 in meter.

          4. The subjects should be able to communicate effectively with study personnel.

          5. The subjects should be able to give written informed consent to participate in the
             study.

             If subject is a female volunteer and

          6. Is of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms,foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence or

          7. Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy has been performed on the subject) or

          8. Should be postmenopausal healthy women who have attained complete menopause and have
             not had menstruation for at least one year and are not on hormone replacement therapy.

          9. Should have 17ß-estradiol serum levels of ≤92 pmol/L, follicle stimulating hormone
             (FSH) of ≥40 IU/L during the screening (only for postmenopausal healthy women)

        Exclusion Criteria:

          1. The subjects who have a history of allergic responses to Ibandronate or other related
             drugs.

          2. The subjects who have significant diseases or clinically significant abnormal findings
             during screening [medical history, physical examination, laboratory evaluations, ECG,
             X-ray and vaginal ultrasonography recordings (only for female subjects)]

          3. The subjects who have any disease or condition which might compromise the
             haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central
             nervous system, diabetes, psychosis or any other body system.

          4. The subjects who have a history or presence of bronchial asthma.

          5. The subject who have used enzyme-modifying drugs within 30 days prior to receiving the
             first dose of study medication.

          6. The subjects who have history of drug dependence, recent history of alcoholism or of
             moderate alcohol uses.

          7. The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or
             more than or equal to 20 biddies per day or those who can not refrain from smoking
             during study period.

          8. The subjects with a history of difficulty with donating blood or difficulty in
             accessibility of veins.

          9. The subjects who have donated 1 unit (350 ml / 450 ml) blood within 90 days prior to
             receiving the first dose of study medication.

         10. The subjects who have a positive hepatitis screen (includes subtypes A, B, C &amp; E).

         11. The subjects who have a positive test result for HIV antibody and / or syphilis
             (RPR/VDRL).

         12. The subject who receives an investigational product, or has participated in a drug
             research study within a period of 90 days prior to the first dose of the study
             medication administration.

         13. Female volunteers demonstrating a positive pregnancy screen.

         14. Female volunteers who are currently breast-feeding.

         15. Female volunteers not willing to use contraception during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Simran Sethi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ibandronate Sodium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

